Celldex Therapeutics, Inc. (CLDX)
- Sector
- Biotechnology
- Last price
- $29.87
- As of
Kresmion compiles this page from CLDX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Celldex Therapeutics, Inc. (CLDX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.
See the full CLDX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CLDX on one page. Preview it with sample data, then open it live with a free account.
Preview the CLDX dossierActive events for CLDX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 7.8%, EPS $-0.96 vs $-1.0413 estimate
- high13F: funds added
4 tracked funds increased CLDX this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +88% to CLDX (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 100% of CLDX (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 96% of CLDX (2026Q2)
FREE, NO ACCOUNT
Every event on CLDX, as it fires
You are seeing 5 of 10 events recorded on CLDX since 2026-05-30.
The five above landed across 3 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
CLDX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC FundCUSIP 15117B202 · 2026Q2 | $43.6M | 0.03% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 15117B202 · 2026Q2 | $24.6M | 0.02% |
| Point72 Asset Management, L.P. FundCUSIP 15117B202 · 2026Q2 | $4.4M | 0.01% |
| D. E. Shaw & Co., Inc. FundCUSIP 15117B202 · 2026Q2 | $663K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CLDX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on CLDX
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in CLDX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on CLDX in the last 180 days.
Upstream: SEC EDGAR filings for CLDX
Kresmion, "Celldex Therapeutics, Inc. (CLDX) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/CLDX. Upstream data: SEC EDGAR filings for CLDX.
Link to this data (HTML):
<a href="https://kresmion.com/research/CLDX">Celldex Therapeutics, Inc. (CLDX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow CLDX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to CLDX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.